Amylin Pharmaceuticals Inc has announced the initiation of a phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the treatment of obesity.
The objective of this dose-ranging study is to support dose selection for phase III, and to inform the ongoing development of a convenient delivery system for this combination regimen. The six-month, randomized, double-blind, placebo-controlled multi-centre study will enrol approximately 600 overweight and obese subjects and is expected to complete in mid-2009.
The details can be read here.
No comments:
Post a Comment